358 related articles for article (PubMed ID: 27091900)
1. Selective Heart Rate Reduction With Ivabradine Increases Central Blood Pressure in Stable Coronary Artery Disease.
Rimoldi SF; Messerli FH; Cerny D; Gloekler S; Traupe T; Laurent S; Seiler C
Hypertension; 2016 Jun; 67(6):1205-10. PubMed ID: 27091900
[TBL] [Abstract][Full Text] [Related]
2. Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease.
Dillinger JG; Maher V; Vitale C; Henry P; Logeart D; Manzo Silberman S; Allée G; Levy BI
Hypertension; 2015 Dec; 66(6):1138-44. PubMed ID: 26418022
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
[TBL] [Abstract][Full Text] [Related]
4. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
Bruguera Cortada J; Varela A
Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
[TBL] [Abstract][Full Text] [Related]
5. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease.
Gloekler S; Traupe T; Stoller M; Schild D; Steck H; Khattab A; Vogel R; Seiler C
Heart; 2014 Jan; 100(2):160-6. PubMed ID: 24186565
[TBL] [Abstract][Full Text] [Related]
6. Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.
Borer JS; Deedwania PC; Kim JB; Böhm M
Am J Cardiol; 2016 Dec; 118(12):1948-1953. PubMed ID: 27780557
[TBL] [Abstract][Full Text] [Related]
7. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
[TBL] [Abstract][Full Text] [Related]
8. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.
Abdel-Salam Z; Rayan M; Saleh A; Abdel-Barr MG; Hussain M; Nammas W
Cardiol J; 2015; 22(2):227-32. PubMed ID: 25179314
[TBL] [Abstract][Full Text] [Related]
9. β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index.
Fischer-Rasokat U; Honold J; Lochmann D; Wolter S; Liebetrau C; Fichtlscherer S; Möllmann H; Spyridopoulos I; Hamm CW
Clin Res Cardiol; 2016 Jun; 105(6):527-34. PubMed ID: 26687495
[TBL] [Abstract][Full Text] [Related]
10. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure.
Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R
Am Heart J; 2013 Oct; 166(4):654-661.e6. PubMed ID: 24093844
[TBL] [Abstract][Full Text] [Related]
11. Effects of ivabradine therapy on heart failure biomarkers.
Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
[TBL] [Abstract][Full Text] [Related]
12. Ivabradine and Bisoprolol on Doppler-derived Coronary Flow Velocity Reserve in Patients with Stable Coronary Artery Disease: Beyond the Heart Rate.
Tagliamonte E; Cirillo T; Rigo F; Astarita C; Coppola A; Romano C; Capuano N
Adv Ther; 2015 Aug; 32(8):757-67. PubMed ID: 26293212
[TBL] [Abstract][Full Text] [Related]
13. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
Tendera M; Talajic M; Robertson M; Tardif JC; Ferrari R; Ford I; Steg PG; Fox K;
Am J Cardiol; 2011 Mar; 107(6):805-11. PubMed ID: 21247517
[TBL] [Abstract][Full Text] [Related]
14. Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study.
Mangiacapra F; Colaiori I; Ricottini E; Balducci F; Creta A; Demartini C; Minotti G; Di Sciascio G
Clin Res Cardiol; 2017 Jan; 106(1):69-75. PubMed ID: 27520989
[TBL] [Abstract][Full Text] [Related]
15. Ivabradine in stable coronary artery disease without clinical heart failure.
Fox K; Ford I; Steg PG; Tardif JC; Tendera M; Ferrari R;
N Engl J Med; 2014 Sep; 371(12):1091-9. PubMed ID: 25176136
[TBL] [Abstract][Full Text] [Related]
16. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy.
Böhm M; Borer JS; Camm J; Ford I; Lloyd SM; Komajda M; Tavazzi L; Talajic M; Lainscak M; Reil JC; Ukena C; Swedberg K
Eur J Heart Fail; 2015 May; 17(5):518-26. PubMed ID: 25801408
[TBL] [Abstract][Full Text] [Related]
17. Ivabradine versus metoprolol for heart rate reduction before coronary computed tomography angiography.
Pichler P; Pichler-Cetin E; Vertesich M; Mendel H; Sochor H; Dock W; Syeda B
Am J Cardiol; 2012 Jan; 109(2):169-73. PubMed ID: 22011557
[TBL] [Abstract][Full Text] [Related]
18. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction.
Rosano GM; Vitale C; Volterrani M
Adv Ther; 2010 Apr; 27(4):202-10. PubMed ID: 20495895
[TBL] [Abstract][Full Text] [Related]
19. Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease.
Weeda ER; Nguyen E; White CM
Ann Pharmacother; 2016 Jun; 50(6):475-85. PubMed ID: 26917820
[TBL] [Abstract][Full Text] [Related]
20. Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.
Majewski S; Slomka S; Zielinska-Wyderkiewicz E; Ciebiada M; Gorski P
Am J Cardiovasc Drugs; 2012 Jun; 12(3):179-88. PubMed ID: 22409211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
